Now showing items 1-16 of 16

    • An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. 

      Sartor, O; Coleman, RE; Nilsson, S; Heinrich, D; Helle, SI; O'Sullivan, JM; Vogelzang, NJ; Bruland, Ø; Kobina, S; Wilhelm, S; Xu, L; Shan, M; Kattan, MW; Parker, C (2017-05)
      Background Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, ...
    • Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. 

      Lorente, D; Omlin, A; Zafeiriou, Z; Nava-Rodrigues, D; Pérez-López, R; Pezaro, C; Mehra, N; Sheridan, E; Figueiredo, I; Riisnaes, R; Miranda, S; Crespo, M; Flohr, P; Mateo, J; Altavilla, A; Ferraldeschi, R; Bianchini, D; Attard, G; Tunariu, N; de Bono, J (2016-12)
      Background The urgent need for castration-resistant prostate cancer molecular characterization to guide treatment has been constrained by the disease's predilection to metastasize primarily to bone. We hypothesized that ...
    • Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. 

      Armstrong, AJ; Saad, F; Phung, D; Dmuchowski, C; Shore, ND; Fizazi, K; Hirmand, M; Forer, D; Scher, HI; Bono, JD (2017-06)
      Background In the AFFIRM trial, enzalutamide significantly increased overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC) after chemotherapy versus placebo and significantly decreased ...
    • Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. 

      Smith, MR; Saad, F; Rathkopf, DE; Mulders, PFA; de Bono, JS; Small, EJ; Shore, ND; Fizazi, K; Kheoh, T; Li, J; De Porre, P; Todd, MB; Yu, MK; Ryan, CJ (2017-07)
      In the COU-AA-302 trial, abiraterone acetate plus prednisone significantly increased overall survival for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). Limited information exists ...
    • DESNT: A Poor Prognosis Category of Human Prostate Cancer. 

      Luca, B-A; Brewer, DS; Edwards, DR; Edwards, S; Whitaker, HC; Merson, S; Dennis, N; Cooper, RA; Hazell, S; Warren, AY; CancerMap Group; Eeles, R; Lynch, AG; Ross-Adams, H; Lamb, AD; Neal, DE; Sethia, K; Mills, RD; Ball, RY; Curley, H; Clark, J; Moulton, V; Cooper, CS (2018-12)
      Background A critical problem in the clinical management of prostate cancer is that it is highly heterogeneous. Accurate prediction of individual cancer behaviour is therefore not achievable at the time of diagnosis leading ...
    • Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. 

      Dearnaley, DP; Jovic, G; Syndikus, I; Khoo, V; Cowan, RA; Graham, JD; Aird, EG; Bottomley, D; Huddart, RA; Jose, CC; Matthews, JHL; Millar, JL; Murphy, C; Russell, JM; Scrase, CD; Parmar, MKB; Sydes, MR (2014-04)
      Background The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with localised prostate cancer. Preliminary findings reported after 5 years of ...
    • Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. 

      James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; Mason, MD; Parker, CC; Ritchie, AWS; Russell, JM; Schiavone, F; Attard, G; de Bono, JS; Birtle, A; Engeler, DS; Elliott, T; Matheson, D; O'Sullivan, J; Pudney, D; Srihari, N; Wallace, J; Barber, J; Syndikus, I; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2016-03)
      Importance The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. ...
    • Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. 

      Page, EC; Bancroft, EK; Brook, MN; Assel, M; Hassan Al Battat, M; Thomas, S; Taylor, N; Chamberlain, A; Pope, J; Raghallaigh, HN; Evans, DG; Rothwell, J; Maehle, L; Grindedal, EM; James, P; Mascarenhas, L; McKinley, J; Side, L; Thomas, T; van Asperen, C; Vasen, H; Kiemeney, LA; Ringelberg, J; Jensen, TD; Osther, PJS; Helfand, BT; Genova, E; Oldenburg, RA; Cybulski, C; Wokolorczyk, D; Ong, K-R; Huber, C; Lam, J; Taylor, L; Salinas, M; Feliubadaló, L; Oosterwijk, JC; van Zelst-Stams, W; Cook, J; Rosario, DJ; Domchek, S; Powers, J; Buys, S; O'Toole, K; Ausems, MGEM; Schmutzler, RK; Rhiem, K; Izatt, L; Tripathi, V; Teixeira, MR; Cardoso, M; Foulkes, WD; Aprikian, A; van Randeraad, H; Davidson, R; Longmuir, M; Ruijs, MWG; Helderman van den Enden, ATJM; Adank, M; Williams, R; Andrews, L; Murphy, DG; Halliday, D; Walker, L; Liljegren, A; Carlsson, S; Azzabi, A; Jobson, I; Morton, C; Shackleton, K; Snape, K; Hanson, H; Harris, M; Tischkowitz, M; Taylor, A; Kirk, J; Susman, R; Chen-Shtoyerman, R; Spigelman, A; Pachter, N; Ahmed, M; Ramon Y Cajal, T; Zgajnar, J; Brewer, C; Gadea, N; Brady, AF; van Os, T; Gallagher, D; Johannsson, O; Donaldson, A; Barwell, J; Nicolai, N; Friedman, E; Obeid, E; Greenhalgh, L; Murthy, V; Copakova, L; Saya, S; McGrath, J; Cooke, P; Rønlund, K; Richardson, K; Henderson, A; Teo, SH; Arun, B; Kast, K; Dias, A; Aaronson, NK; Ardern-Jones, A; Bangma, CH; Castro, E; Dearnaley, D; Eccles, DM; Tricker, K; Eyfjord, J; Falconer, A; Foster, C; Gronberg, H; Hamdy, FC; Stefansdottir, V; Khoo, V; Lindeman, GJ; Lubinski, J; Axcrona, K; Mikropoulos, C; Mitra, A; Moynihan, C; Rennert, G; Suri, M; Wilson, P; Dudderidge, T; IMPACT Study Collaborators; Offman, J; Kote-Jarai, Z; Vickers, A; Lilja, H; Eeles, RA (2019-12)
      Background Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 ...
    • Low-risk Prostate Cancer: Identification, Management, and Outcomes. 

      Moschini, M; Carroll, PR; Eggener, SE; Epstein, JI; Graefen, M; Montironi, R; Parker, C (2017-08)
      Context The incidence of low-risk prostate cancer (PCa) has increased as a consequence of prostate-specific antigen testing.Objective In this collaborative review article, we examine recent literature regarding low-risk ...
    • Managing Nonmetastatic Castration-resistant Prostate Cancer. 

      Mateo, J; Fizazi, K; Gillessen, S; Heidenreich, A; Perez-Lopez, R; Oyen, WJG; Shore, N; Smith, M; Sweeney, C; Tombal, B; Tomlins, SA; de Bono, JS (2019-02)
      CONTEXT:Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have rising prostate-specific antigen (PSA) and castrate testosterone levels, with no radiological findings of metastatic disease on computed ...
    • Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer. 

      Kishan, AU; Tendulkar, RD; Tran, PT; Parker, CC; Nguyen, PL; Stephenson, AJ; Carrie, C (2018-05-15)
      Context Currently, salvage radiotherapy (SRT) is the only known curative intervention for men with recurrent disease following prostatectomy. Critical issues in the optimal selection and management of men being considered ...
    • Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer. 

      Reis Ferreira, M; Khan, A; Thomas, K; Truelove, L; McNair, H; Gao, A; Parker, CC; Huddart, R; Bidmead, M; Eeles, R; Khoo, V; van As, NJ; Hansen, VN; Dearnaley, DP (2017-12)
      Purpose To investigate the feasibility of dose escalation and hypofractionation of pelvic lymph node intensity modulated radiation therapy (PLN-IMRT) in prostate cancer (PCa).Methods and materials In a phase 1/2 study, ...
    • Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). 

      Mehra, N; Dolling, D; Sumanasuriya, S; Christova, R; Pope, L; Carreira, S; Seed, G; Yuan, W; Goodall, J; Hall, E; Flohr, P; Boysen, G; Bianchini, D; Sartor, O; Eisenberger, MA; Fizazi, K; Oudard, S; Chadjaa, M; Macé, S; de Bono, JS (2018-09)
      BACKGROUND:Noninvasive biomarkers are needed to guide metastatic castration-resistant prostate cancer (mCRPC) treatment. OBJECTIVE:To clinically qualify baseline and on-treatment cell-free DNA (cfDNA) concentrations as ...
    • Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. 

      Seibert, TM; Fan, CC; Wang, Y; Zuber, V; Karunamuni, R; Parsons, JK; Eeles, RA; Easton, DF; Kote-Jarai, Z; Al Olama, AA; Garcia, SB; Muir, K; Grönberg, H; Wiklund, F; Aly, M; Schleutker, J; Sipeky, C; Tammela, TL; Nordestgaard, BG; Nielsen, SF; Weischer, M; Bisbjerg, R; Røder, MA; Iversen, P; Key, TJ; Travis, RC; Neal, DE; Donovan, JL; Hamdy, FC; Pharoah, P; Pashayan, N; Khaw, K-T; Maier, C; Vogel, W; Luedeke, M; Herkommer, K; Kibel, AS; Cybulski, C; Wokolorczyk, D; Kluzniak, W; Cannon-Albright, L; Brenner, H; Cuk, K; Saum, K-U; Park, JY; Sellers, TA; Slavov, C; Kaneva, R; Mitev, V; Batra, J; Clements, JA; Spurdle, A; Teixeira, MR; Paulo, P; Maia, S; Pandha, H; Michael, A; Kierzek, A; Karow, DS; Mills, IG; Andreassen, OA; Dale, AM; PRACTICAL Consortium* (2018-01-10)
      Objectives To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age.Design Analysis of genotype, PCa status, and age to ...
    • Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. 

      Mikropoulos, C; Selkirk, CGH; Saya, S; Bancroft, E; Vertosick, E; Dadaev, T; Brendler, C; Page, E; Dias, A; Evans, DG; Rothwell, J; Maehle, L; Axcrona, K; Richardson, K; Eccles, D; Jensen, T; Osther, PJ; van Asperen, CJ; Vasen, H; Kiemeney, LA; Ringelberg, J; Cybulski, C; Wokolorczyk, D; Hart, R; Glover, W; Lam, J; Taylor, L; Salinas, M; Feliubadaló, L; Oldenburg, R; Cremers, R; Verhaegh, G; van Zelst-Stams, WA; Oosterwijk, JC; Cook, J; Rosario, DJ; Buys, SS; Conner, T; Domchek, S; Powers, J; Ausems, MG; Teixeira, MR; Maia, S; Izatt, L; Schmutzler, R; Rhiem, K; Foulkes, WD; Boshari, T; Davidson, R; Ruijs, M; Helderman-van den Enden, AT; Andrews, L; Walker, L; Snape, K; Henderson, A; Jobson, I; Lindeman, GJ; Liljegren, A; Harris, M; Adank, MA; Kirk, J; Taylor, A; Susman, R; Chen-Shtoyerman, R; Pachter, N; Spigelman, A; Side, L; Zgajnar, J; Mora, J; Brewer, C; Gadea, N; Brady, AF; Gallagher, D; van Os, T; Donaldson, A; Stefansdottir, V; Barwell, J; James, PA; Murphy, D; Friedman, E; Nicolai, N; Greenhalgh, L; Obeid, E; Murthy, V; Copakova, L; McGrath, J; Teo, S-H; Strom, S; Kast, K; Leongamornlert, DA; Chamberlain, A; Pope, J; Newlin, AC; Aaronson, N; Ardern-Jones, A; Bangma, C; Castro, E; Dearnaley, D; Eyfjord, J; Falconer, A; Foster, CS; Gronberg, H; Hamdy, FC; Johannsson, O; Khoo, V; Lubinski, J; Grindedal, EM; McKinley, J; Shackleton, K; Mitra, AV; Moynihan, C; Rennert, G; Suri, M; Tricker, K; IMPACT study collaborators; Moss, S; Kote-Jarai, Z; Vickers, A; Lilja, H; Helfand, BT; Eeles, RA (2018-01-04)
      BACKGROUND:Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition ...
    • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. 

      Scher, HI; Morris, MJ; Stadler, WM; Higano, C; Basch, E; Fizazi, K; Antonarakis, ES; Beer, TM; Carducci, MA; Chi, KN; Corn, PG; de Bono, JS; Dreicer, R; George, DJ; Heath, EI; Hussain, M; Kelly, WK; Liu, G; Logothetis, C; Nanus, D; Stein, MN; Rathkopf, DE; Slovin, SF; Ryan, CJ; Sartor, O; Small, EJ; Smith, MR; Sternberg, CN; Taplin, M-E; Wilding, G; Nelson, PS; Schwartz, LH; Halabi, S; Kantoff, PW; Armstrong, AJ; Prostate Cancer Clinical Trials Working Group 3 (2016-04)
      Purpose Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations ...